E Fund Management Co. Ltd. acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,359 shares of the company’s stock, valued at approximately $1,356,000.
Other institutional investors and hedge funds have also modified their holdings of the company. MUFG Securities EMEA plc acquired a new stake in Moderna during the second quarter worth $28,000. Allied Private Wealth LLC acquired a new position in shares of Moderna in the 2nd quarter valued at $30,000. Canton Hathaway LLC acquired a new position in shares of Moderna in the 1st quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of Moderna by 35.1% during the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the period. 75.33% of the stock is currently owned by institutional investors.
Moderna Price Performance
Shares of MRNA stock opened at $174.38 on Thursday. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The stock has a market capitalization of $69.62 billion, a PE ratio of -21.82 and a beta of 0.91. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock’s fifty day moving average is $64.91 and its 200-day moving average is $54.84.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Loop Capital set a $135.00 price objective on Moderna in a research note on Wednesday. Citigroup raised their target price on Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. William Blair raised Moderna from a “market perform” rating to an “outperform” rating in a research note on Wednesday. Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research report on Wednesday. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $120.00 price objective on shares of Moderna in a research note on Wednesday. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $56.56.
Read Our Latest Analysis on MRNA
Key Stories Impacting Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Phase 3 melanoma trial met both key endpoints. Intismeran, Moderna’s individualized mRNA neoantigen therapy, combined with Merck’s Keytruda, significantly improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with resected, high-risk melanoma. The companies described the results as the first positive late-stage trial for a personalized mRNA cancer vaccine. Merck and Moderna Phase 3 trial announcement
- Positive Sentiment: The results support a broader cancer-treatment opportunity. Analysts and medical commentators said the outcome could validate Moderna’s mRNA platform for treating cancer and potentially open development opportunities across additional tumor types. The vaccine is tailored to mutations in an individual patient’s tumor, offering a potentially differentiated approach to personalized oncology. Moderna and Merck cancer vaccine breakthrough
- Positive Sentiment: Additional developments added to the bullish sentiment. The FDA approved Moderna’s first mRNA-based seasonal influenza vaccine, mFLUSIVA, while William Blair upgraded the stock to “outperform” and Bank of America moved its rating from “underperform” to “neutral.” FDA approval of Moderna mFLUSIVA
- Neutral Sentiment: Investors are awaiting detailed trial data. Moderna and Merck released topline results, but analysts said full efficacy, safety and durability data will be important for assessing regulatory timing and the vaccine’s commercial potential.
- Negative Sentiment: The sharp rally raises execution and valuation risks. The move triggered substantial losses for short sellers and increased options activity, while the stock now reflects much higher expectations for successful approval, manufacturing and adoption. Any disappointing detailed data or regulatory delays could lead to volatility.
Insiders Place Their Bets
In related news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares of the company’s stock, valued at $3,373,400. This trade represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by insiders.
About Moderna
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Read More
- Five stocks we like better than Moderna
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
